Overview

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put NantKwest, Inc.'s financial performance into perspective.
NK (Common Stock) $3.620.00 (0.00%)
Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest News

NantKwest Announces FDA Grant of Orphan Drug Designation for the Company’s aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma

Mar 20, 2017 | Press Releases

CULVER CITY, Calif.--(BUSINESS WIRE)--Mar. 20, 2017-- NantKwest, Inc. (Nasdaq:N

Read More

NantKwest to Present at Upcoming Investor Conferences

Mar 06, 2017 | Press Releases

CULVER CITY, Calif.--(BUSINESS WIRE)--Mar. 6, 2017-- NantKwest (Nasdaq:NK) toda

Read More

Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer

Jan 23, 2017 | Press Releases

CULVER CITY, Calif.--(BUSINESS WIRE)--Jan. 23, 2017-- NantKwest Inc. (Nasdaq:NK

Read More

Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Nantkwest Inc posts new information to the site. Just enter your e-mail address and click Submit.